Submit Request Quote
 * Denotes Required Field.
Name:
 *
Company Name:
Phone:
Email:
 *
Message:
Request Quote
 
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Goat Anti-Rhesus IgA [GARI]

Product Type: Reagents for IgA Detection
Format: Anti-rhesus IgA, polyclonal goat IgG
Clone ID: [GARI]
RRID: AB_3086850
Common Names: Goat Anti-Rhesus IgA [GARI] | Goat Anti-Rhesus IgA [SBCS-58] | CAT-00366
Target: IgA
Reactivity:
Applications: in vitro in vitro; ELISA
Description:

GARI: purified goat IgG from the serum of a goat immunized with rhesus IgA. This product has minimal cross-reactivity with rhesus IgG and human IgM. Unconjugated.

This unconjugated goat polyclonal antibody was generated by immunizing a single Alpine-cross goat with serum-purified IgA isolated from a genetically diverse pool of rhesus macaques. The resulting goat IgG was purified by antigen-specific affinity chromatography and extensively cross-adsorbed against rhesus IgG and human IgM to reduce off-target binding.

Importantly, each lot of this reagent reflects the polyclonal response of a single immunized animal, and as such, performance characteristics—such as epitope breadth and relative signal intensity—may vary slightly between lots. Researchers are encouraged to validate each lot within their assay context and to consult NHPRR for bulk reservations if consistent lot use is required across a study.

This antibody demonstrates strong and specific recognition of both monomeric and dimeric forms of rhesus IgA, including antigen-bound IgA (e.g., SARS-CoV-2 RBD complexes), with minimal cross-reactivity to rhesus IgG or human IgM. It is suitable for detecting diverse rhesus IgA allotypes and is optimized for ELISA; compatibility with other applications such as Western blot or immunohistochemistry should be evaluated empirically.

 

Recommended Use:

Quantifying mucosal or systemic IgA responses in rhesus macaque models of infection, vaccination, or mucosal immunity. The unconjugated format offers flexibility for use with user-selected secondary antibodies. Conjugated versions (HRP and biotin) are available.

 

Supporting Data:

Binding curves of anti-rhesus IgA assessed by ELISA.

Binding of HRP-conjugated (A), non-conjugated (B), and biotin-conjugated (C) anti-rhesus IgA polyclonal antibody (pAb) to monomeric IgA (mIgA) and dimeric IgA (dIgA) in their unbound (free) and RBD-bound forms. Each graph shows absorbance (450 nm) as a function of anti-rhesus IgA concentration (nM). For (A), HRP-conjugated pAb binding to mIgA (unbound: pink, RBD-bound: purple) and dIgA (unbound: blue, RBD-bound: cyan) was measured directly. (B) Non-conjugated pAb exhibited comparable binding trends across the conditions, and (C) biotin-conjugated pAb revealed differential binding, particularly with RBD-bound mIgA. Data points represent mean values of three replicates, with error bars indicating standard deviations (SD). Dotted lines represent the average of control wells (n=2 for HRP and n=6 for the non-conjugated and biotin).

 

Modifications: None
Restrictions: No
Sponsor: NIAID

Reagent cost, which is the actual cost of production, is recovered for some reagents. Please inquire if you have questions about reagent cost recovery. Purchase order or credit card is NOW REQUIRED for cost-recovered reagents.

You are not authorized to purchase this product. Please ensure you are logged into your account.